- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case C-138/15 P: Judgment of the Court (Sixth Chamber) of 3 March 2016 — Teva Pharma BV, Teva Pharmaceuticals Europe BV v European Medicines Agency (EMA), European Commission (Appeal — Orphan medicinal products — Regulation (EC) No 141/2000 — Regulation (EC) No 847/2000 — Refusal to grant marketing authorisation for the generic version of the orphan medicinal product ‘imatinib mesylate’)
ECLI:EU:UNKNOWN:62015CA0138
62015CA0138
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Official Journal of the European Union
C 156/16
(Case C-138/15 P) (<span class="super">1</span>)
((Appeal - Orphan medicinal products - Regulation (EC) No 141/2000 - Regulation (EC) No 847/2000 - Refusal to grant marketing authorisation for the generic version of the orphan medicinal product ‘imatinib mesylate’))
(2016/C 156/22)
Language of the case: English
Parties
Appellants: Teva Pharma BV, Teva Pharmaceuticals Europe BV (represented by: K. Bacon QC, E. Mackenzie, Barrister, and G. Morgan, Solicitor)
Other parties to the proceedings: European Medicines Agency (EMA) (represented by: N. Rampal Olmedo, M. Tovar Gomis, S. Marino and T. Jabłoński, acting as Agents), European Commission (represented by: A. Sipos and M. Šimerdová, acting as Agents)
Operative part of the judgment
The Court:
1.Dismisses the appeal.
2.Orders Teva Pharma BV and Teva Pharmaceuticals Europe BV to bear their own costs and to pay the costs incurred by the European Medicines Agency (EMA).
3.Orders the European Commission to bear its own costs.
(<span class="super">1</span>) OJ C 190, 8.6.2015.